A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment

Trial Profile

A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs Mibefradil (Primary) ; Temozolomide
  • Indications Anaplastic astrocytoma; Astrocytoma; Ependymoma; Glioblastoma; Glioma; Oligodendroglioma
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Dec 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 28 Jul 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov
    • 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top